INmune Bio, Inc. (NASDAQ:INMB) Q4 2022 Earnings Call Transcript

RJ Tesi: Well, okay. Thank you. So thank you, everyone for participating in the call. We continue to make progress despite the regulatory challenges and the dislocations in the capital markets. We believe we have novel products that will be valuable to clinical teams and have a broad variety of clinical applications, and you’re beginning to see that. And we aren’t afraid to innovate in our clinical, regulatory and financial activities. INmune Bio has this can-do attitude that we think will benefit patients and investors alike. And I personally will put Alzheimer’s disease and prostate cancer on notice. We’re coming after you. So with that, we will close, and thank you very much.

Operator: This concludes today’s conference. You may disconnect your lines at this time. Thank you for your participation.